Related Experiment Video
Updated: Jan 12, 2026
Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Impact of Fungal Sensitization on Long-Term Outcomes in Severe Asthma
Robin Réau1, Pascale Nicaise2, Axelle Dupont3
1Service de Pneumologie, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France.
Background:
Fungal sensitization has been associated with some features of severe asthma, but whether severe asthma with fungal sensitization (SAFS) requires specific management remains unclear. The long-term outcomes of SAFS remain poorly studied.
Objective:
To assess the impact of fungal sensitization on disease severity using the Asthma Severity Scoring System (ASSESS) score and its evolution over time in a severe asthma cohort.
Methods:
This retrospective analysis included adult patients with severe asthma evaluated at Bichat Hospital (Paris, France) between 2017 and 2022. All patients underwent specific IgE testing for Aspergillus, Botrytis, Alternaria, Penicillium, Cladosporium, and Candida. SAFS was defined as the presence of at least 1 positive specific IgE result.
Results:
Among the 245 patients included, 69 (28.2%) had SAFS. At baseline, the ASSESS score was significantly higher in the SAFS group than in the severe asthma without fungal sensitization (SAwoFS) group (13.7 ± 2.8 vs 12.0 ± 3.0; P < .0001). This greater severity was supported by a lower FEV1 (65.5% vs 76.5% predicted; P = .0007), higher daily oral corticosteroid use (36.2% vs 18.2%; P = .0026), and higher hospitalization rates over the last 6 months (36.2% vs 19.9%; P = .007). At 12 months, the mean ASSESS score significantly decreased in both groups (SAFS: 12.4 ± 3.4; SAwoFS: 10.2 ± 3.6; P = .00015), but remained significantly higher in the SAFS group, driven by persistently lower FEV1 (65% vs 80% predicted; P = .0006), higher exacerbation rate (74.6% vs 55.3%; P = .008), and higher daily oral corticosteroid use (30% vs 14.7%; P = .009). Biologics were initiated in 51% of patients with SAFS and 56% of patients with SAwoFS. Among patients treated with biologics, ASSESS scores remained significantly higher in the SAFS group (12.8 vs 10.0; P = .0015).
Conclusions:
Patients with SAFS represent a particularly severe asthma phenotype, even after treatment with biologics. Nonetheless, they show a significant response to standardized care for severe asthma.
More Related Videos
10:06Efficient Method for Imaging Murine Lungs that Preserves Spatial Dynamics of Fungal Spores in the Airways
Published on: December 13, 2024
15:01Confocal Laser Scanning Microscopy-Based Quantitative Analysis of Aspergillus fumigatus Conidia Distribution in Whole-Mount Optically Cleared Mouse Lung
Published on: September 18, 2021
Related Concept Videos
01:24Asthma-III: Symptoms and Complications
Classification of Asthma
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
01:28Fungal Phylum Microsporidia